【摘要】 二代益生菌来源于可干预人类疾病的肠道微生物群，是目前治疗肠道炎症、免疫功能障碍、代谢紊乱及癌症的新型候选药物之一。针对二代益生菌开发的多个生物药已进入临床前或临床研究，然而疗效不足、剂量不可控等问题是二代益生菌开发成药物的难点，使二代益生菌可控的肠道定殖是解决上述难点问题的关键。综述基于药物研发的二代益生菌的临床进展，重点关注影响其定殖的因素及作用机制，并对增强二代益生菌肠道适应力的策略进行总结，为解决目前二代益生菌临床开发中的问题提供参考。更多还原

【Abstract】 Derived from gut microbiota that can intervene in human diseases, next generation probiotics are one of the novel drug candidates available for the treatment of intestinal inflammation, immune dysfunction, metabolic disorders and cancer. Several biopharmaceuticals developed for next generation probiotics have entered the stage of preclinical or clinical studies, however, insufficient efficacy and uncontrollable dosage are the challenges in the development of next generation probiotics into drugs. To solve these problems,intestinal colonization making next generation probiotics controllable is a possible way. This review introduces the clinical progress of next generation probiotics based on drug development, focusing on the factors and their mechanisms affecting the intestinal colonization of next generation probiotics, and summarizes the strategies to enhance the intestinal resilience of next generation probiotics, aiming to provide some ideas for solving the current problems in clinical development of next generation probiotics.更多还原